| Long-term follow-up (four years) of unprotected left main coronary artery disease treated with paclitaxel-eluting stents (from the TRUE Registry). | |
| | |
MedLine Citation:
|
PMID: 20542775 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
AIMS: Limited data are available on the long-term outcome following PCI with paclitaxel-eluting stent (PES) implantation in patients with unprotected left main coronary artery (LMCA). The objective of this study was to evaluate "real world" long-term outcome following paclitaxel-eluting stent (PES) implantation for unprotected LMCA disease in patients enrolled in the TRUE registry. METHODS AND RESULTS: From March 2003 to October 2004, 93 consecutive patients (81.7% male) underwent PCI for unprotected LMCA disease. Surveillance angiography was performed at 6.8+/-3.3 months follow-up. The target lesion involved the distal LMCA in 68 (73.1%) patients. Double stenting techniques were performed in 46 (67.6%) distal LMCA, of these 50% were stented using the Crush technique. Clinical follow-up was complete in all patients with 85.8% angiographic follow-up rate. In-segment restenosis occurred in 16 (20.3%) patients and was focal in 72.4% of cases and significantly higher in patients with distal LMCA (36.8% vs. 13.6%, p<0.04). At a median follow-up of 1,450 days (IQR 1281-1595), the overall incidence of MACE was 35.5% and the TLR rate was 25.8% and significantly higher in patients with bifurcation stenting (32.3% vs. 8%, p<0.02). The estimated cardiac survival rate at one and four years was 96.7% and 93.3%, respectively. Total mortality rate was 14.1% and cardiac was 6.5%. There was one (1.1%) definite stent thrombosis (ST) and one (1.1%) probable ST. CONCLUSIONS: Treatment of unprotected LMCA disease with PES, after four years follow-up, appears to be safe and effective with a low rate of cardiac mortality and overall risk of ST. The need for target lesion revascularisation in 25.8% of patients highlights the need for more effective PCI especially in patients with distal LMCA disease. |
| | |
Authors:
|
Cosmo Godino; Guido Parodi; Shinichi Furuichi; Azeem Latib; Rossella Barbagallo; Omer Goktekin; Michela Cera; Ralf Mueller; Corrado Tamburino; Eberhard Grube; Carlo Di Mario; Bernard Reimers; Alaide Chieffo; David Antoniucci; Antonio Colombo; Giuseppe M Sangiorgi |
Related Documents
:
|
23554855 - Outcomes of optimized over standard protocol of rabbit antithymocyte globulin for sever... 21733455 - Star™ ankle: long-term results. 19717185 - Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction ... 8197975 - Clinical and angiographic follow-up after coronary angioplasty in patients with two-ves... 3545965 - Failure of a cytoprotective dose of arbaprostil to heal acute duodenal ulcers. results ... 17765775 - Prospective, randomized, controlled trial of a hemostatic sealant in children undergoin... |
Publication Detail:
|
Type: Journal Article; Multicenter Study |
Journal Detail:
|
Title: EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology Volume: 5 ISSN: 1969-6213 ISO Abbreviation: EuroIntervention Publication Date: 2010 Apr |
Date Detail:
|
Created Date: 2010-06-14 Completed Date: 2010-09-27 Revised Date: 2011-02-22 |
Medline Journal Info:
|
Nlm Unique ID: 101251040 Medline TA: EuroIntervention Country: France |
Other Details:
|
Languages: eng Pagination: 906-16 Citation Subset: IM |
Affiliation:
|
San Raffaele Institute, Milan, Italy. cosmogodino@gmail.com <cosmogodino@gmail.com> |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Aged, 80 and over Angioplasty, Balloon, Coronary / adverse effects, instrumentation*, mortality Cardiovascular Agents / administration & dosage* Chi-Square Distribution Coronary Angiography Coronary Artery Disease / mortality, radiography, therapy* Coronary Restenosis / etiology Disease-Free Survival Drug-Eluting Stents* Europe / epidemiology Female Follow-Up Studies Hospital Mortality Humans Kaplan-Meier Estimate Logistic Models Male Middle Aged Myocardial Infarction / etiology Paclitaxel / administration & dosage* Prosthesis Design Registries Risk Assessment Risk Factors Severity of Illness Index Thrombosis / etiology Time Factors Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Cardiovascular Agents; 33069-62-4/Paclitaxel |
| Comments/Corrections | |
Comment In:
|
EuroIntervention. 2011 Feb;6(7):904-5
[PMID:
21252030
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Paclitaxel and sirolimus eluting stents versus bare metal stents: long-term risk of stent thrombosis...
Next Document: Carotid artery revascularisation in high-surgical-risk patients with the NexStent and the FilterWire...